Skip to main content
SpringerLink
Log in

Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Following treatment of mediastinal Hodgkin's disease (HD), residual masses are frequent and gallium scanning has proven to be of value in the evaluation of their specificity (fibrosis or active disease). This study assessed, for relapse and survival, the predictive value of restaging gallium scan of patients with a residual mass on computed tomography scan after induction chemotherapy. Between 1/89 and 12/97, in 53 newly diagnosed HD patients with a residual mediastinal mass, a gallium scan was performed after chemotherapy (3 or 4 courses) and always before consolidative radiotherapy. Characteristics at diagnosis were: nodular sclerosis histology, 89%; bulky mediastinal disease, 79%; B-symptoms, 51%. Results: gallium scan was positive in 16 patients (30%) and negative in 37 (70%). At median follow-up period of 36 months, freedom-from-progression rate was 86% versus 19% (P<0.0001) for patients with negativevs positive gallium scans, respectively. The 5-year overall survival (OS) rate was 68% and differed significantly (P<0.0001) between negative (91%) and positive (25%) gallium scanning groups. The specificity of gallium scanning was 91% and the sensitivity 72% with a positive predictive value of 81% and a negative predictive value of 86%. Evaluation with gallium scan after induction chemotherapy identifies chemosensitive patients among those with poorprognosis mediastinal HD. Although relapse may occur in patients with negative gallium scan, a postive gallium scan is highly predictive of failure and poor outcome, and treatment should thus be modified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Carde Pet al. Clinical stages I and II Hodgkin's disease a specifically tailored therapy according to prognostic factors.J Clin Oncol 1988;6: 239–252.

    Article  CAS  PubMed  Google Scholar 

  2. Strauss DJet al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross resistant chemotherapy and intermediate-dose radiotherapy.J. Clin Oncol 1990;8: 1173–1186.

    Article  Google Scholar 

  3. Israel Oet al. Gallium-67 imaging in monitoring lymphoma response to treatment.Cancer 1988;61: 2439–2443.

    Article  CAS  PubMed  Google Scholar 

  4. Kostakoglu Let al. Validation of gallium-67-citrate single photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum.J Nucl Med 1992;33: 345–350.

    CAS  PubMed  Google Scholar 

  5. McLaughlin AF, Southee AE. Gallium scintigraphy in tumor diagnosis and management. In: IPC Murray, PJ EII (eds.).Nuclear Medicine in Clinical Diagnosis and Treatment, vol. 2. Churchill Livingstone: Edinburgh, 1994, pp 711–725.

    Google Scholar 

  6. Wylie BRet al. Gallium scanning in the management of mediastinal Hodgkin's disease.Eur J Haematol 1989;42: 344–347.

    Article  CAS  PubMed  Google Scholar 

  7. Southee AEet al. Gallium scanning as a predictor of outcome in mediastinal Hodgkin's disease.Eur J Nucl Med 1989;15: 547–551.

    Google Scholar 

  8. Kaplan WDet al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma.J Clin Oncol 1990;8: 1966–1970.

    Article  CAS  PubMed  Google Scholar 

  9. Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients.Semin Nucl Med 1995;25: 60–71.

    Article  CAS  PubMed  Google Scholar 

  10. King SC, Reiman RJ, Prosnitz LR. Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease.J Clin Oncol 1994;12: 306–3111.

    Article  CAS  PubMed  Google Scholar 

  11. Hagemeister FBet al. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy.Ann Oncol 1994;5(Suppl 2): 59–63.

    Article  PubMed  Google Scholar 

  12. Janicek Met al. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.J Clin Oncol 1997;15: 1631–1637.

    Article  CAS  PubMed  Google Scholar 

  13. Tumeh SSet al. Lymphoma: evaluation with Ga-67 SPECT.Radiology 1987;164: 111–114.

    Article  CAS  PubMed  Google Scholar 

  14. Brice Pet al. Residual mediastinal mass in malignant lymphoma: value of magnetic resonance imaging and gallium scan.Nouv Rev Fr Hematol 1993;35: 457–451.

    CAS  PubMed  Google Scholar 

  15. Hubner KF, Buonocore E, Singh SK, Gould HR, Cotten DW. Characteriation of chest masses by FDG positron emission tomography.Clin Nucl Med 1995;20: 293–298.

    Article  CAS  PubMed  Google Scholar 

  16. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease.N Engl J Med 1998;339: 1506–1514.

    Article  CAS  PubMed  Google Scholar 

  17. Cheson BDet al. Report of an international workshop to standardize response criteria for non Hodgkin's lymphomas.J Clin Oncol 1999;17: 1244–1253.

    Article  CAS  PubMed  Google Scholar 

  18. Kaplan ES, Meier P. Non parametric estimation from incomplete observations.J Am Stat Assoc 1958;53: 457–461.

    Article  Google Scholar 

  19. Andre Met al. Results of 3 courses of ABVD with subtotal nodal irradiation in 189 patients with nodal Hodgkin's disease (stage I, II, IIA).Hematol Cell Ther 1997;39: 59–65.

    Article  CAS  PubMed  Google Scholar 

  20. Ferme Cet al. Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognotic models using 344 patients included in the GELA study.Cancer 1997;80: 1124–1133.

    Article  CAS  PubMed  Google Scholar 

  21. Harris EW, Rakow JI, Weiner M, Agress H Jr. Thallium-201 scintigraphy for assessement of a gallium-67-avid mediastinal mass following therapy for Hodgkins disease.J Nucl Med 1993;34: 1326–1330.

    CAS  PubMed  Google Scholar 

  22. Gasparini MDet al. Current role of Gallium scan and magnetic resonance imaging in the management of mediastinal Hodgkin lymphoma.Cancer 1993;72: 577–582.

    Article  CAS  PubMed  Google Scholar 

  23. Salloum Eet al. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients.J Clin Oncol 1997;15: 518–527.

    Article  CAS  PubMed  Google Scholar 

  24. Bartold SPet al. Procedure guideline for gallium scintigraphy in the evaluation of malignant disease.J Nucl Med 1997;38: 990–994.

    CAS  PubMed  Google Scholar 

  25. Bogart JAet al. The value of gallium imaging after therapy for Hodgkin's disease.Cancer 1998;82: 754–759.

    Article  CAS  PubMed  Google Scholar 

  26. Jerusalem Get al. Whole body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma.Nucl Med Commun 1999;20: 13–20.

    Article  CAS  PubMed  Google Scholar 

  27. Cremerius Uet al. Clinical value of FDG PET for therapy monitoring of malignant lymphoma-results of a retrospective study in 72 patients.Nuklearmedizin 1999;38: 24–30.

    CAS  PubMed  Google Scholar 

  28. Devizzi Let al. Comparison of gallium scan, computed tomography and magnetic resonance in patients with mediastinal Hodgkin's disease.Ann Oncol 1997;8 (Suppl 1): 53–57.

    Article  PubMed  Google Scholar 

  29. Jerusalem Get al. Whole-body positron emission tomography using FDG-PET for posttreatment evaluation of Hodgkins disease and non-Hodgkins lymphoma has higher diagnosistic and prognostic value than classical CT scan imaging.Blood 1999;94: 429–433.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d'Hématologie, Hopital Saint-Louis, AP-HP, Paris, France

    I Ionescu, P Brice, D Simon, P Rousselot & C Gisselbrecht

  2. HDJ d'Hématologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France

    P Brice

  3. Service de Radiologie, Hopital Saint-Louis, AP-HP, Paris, France

    A Guermazi

  4. Service de Pédiatrie Hématologique, Hopital Saint-Louis, AP-HP, Paris, France

    T Leblanc

  5. Service de Chirurgie, Hopital Saint-Louis, AP-HP, Paris, France

    D Gossot

  6. Service d'Anatomie Pathologique, Hopital Saint-Louis, AP-HP, Paris, France

    V Meignin

  7. Service de Médecine Nucléaire, Hopital Saint-Louis, AP-HP, Paris, France

    JD Rain

Authors
  1. I Ionescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Brice
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Guermazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Leblanc
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Rousselot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Gossot
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. V Meignin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Gisselbrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. JD Rain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Brice.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ionescu, I., Brice, P., Simon, D. et al. Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients. Med Oncol 17, 127–134 (2000). https://doi.org/10.1007/BF02796208

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02796208

Keywords

Search

Navigation